Monoclonal antibodies directed against tumor necrosis factor alpha (anti-TNF-alpha agents) have dramatically changed the therapeutical approach to inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. A new anti-TNF drug, golimumab, has recently been approved for patients with moderate to severe ulcer-ative colitis. Its efficacy has been demonstrated by preclinical and clinical studies and the drug showed an efficacy and safety profile in line with the other anti-TNF agents, such as infliximab and adalimumab. This review gives an overview on golimumab in the treatment of moderate to severe ulcerative colitis.
GOLIMUMAB: CLINICAL UPDATE ON ITS USE FOR ULCERATIVE COLITIS / Gilardi, D; Fiorino, G; Allocca, M; Bravata, I; Danese, S. - In: DRUGS OF TODAY. - ISSN 1699-3993. - 51:3(2015), pp. 171-184. [10.1358/dot.2015.51.3.2298240]
GOLIMUMAB: CLINICAL UPDATE ON ITS USE FOR ULCERATIVE COLITIS
Danese S
2015-01-01
Abstract
Monoclonal antibodies directed against tumor necrosis factor alpha (anti-TNF-alpha agents) have dramatically changed the therapeutical approach to inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. A new anti-TNF drug, golimumab, has recently been approved for patients with moderate to severe ulcer-ative colitis. Its efficacy has been demonstrated by preclinical and clinical studies and the drug showed an efficacy and safety profile in line with the other anti-TNF agents, such as infliximab and adalimumab. This review gives an overview on golimumab in the treatment of moderate to severe ulcerative colitis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
